» Articles » PMID: 21763507

Multifaceted Counter-APOBEC3G Mechanisms Employed by HIV-1 Vif

Overview
Journal J Mol Biol
Publisher Elsevier
Date 2011 Jul 19
PMID 21763507
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

In the absence of human immunodeficiency virus type 1 (HIV-1) Vif protein, the host antiviral deaminase apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (A3G) restricts the production of infectious HIV-1 by deamination of dC residues in the negative single-stranded DNA produced by reverse transcription. The Vif protein averts the lethal threat of deamination by precluding the packaging of A3G into assembling virions by mediating proteasomal degradation of A3G. In spite of this robust Vif activity, residual A3G molecules that escape degradation and incorporate into newly assembled virions are potentially deleterious to the virus. We hypothesized that virion-associated Vif inhibits A3G enzymatic activity and therefore prevents lethal mutagenesis of the newly synthesized viral DNA. Here, we show that (i) Vif-proficient HIV-1 particles released from H9 cells contain A3G with lower specific activity compared with Δvif-virus-associated A3G, (ii) encapsidated HIV-1 Vif inhibits the deamination activity of recombinant A3G, and (iii) purified HIV-1 Vif protein and the Vif-derived peptide Vif25-39 inhibit A3G activity in vitro at nanomolar concentrations in an uncompetitive manner. Our results manifest the potentiality of Vif to control the deamination threat in virions or in the pre-integration complexes following entry to target cells. Hence, virion-associated Vif could serve as a last line of defense, protecting the virus against A3G antiviral activity.

Citing Articles

The Disassociation of A3G-Related HIV-1 cDNA G-to-A Hypermutation to Viral Infectivity.

Martin J, Chen X, Jia X, Shao Q, Liu B Viruses. 2024; 16(5).

PMID: 38793610 PMC: 11126051. DOI: 10.3390/v16050728.


Direct inhibition of human APOBEC3 deaminases by HIV-1 Vif independent of the proteolysis pathway.

Kamba K, Wan L, Unzai S, Morishita R, Takaori-Kondo A, Nagata T Biophys J. 2023; 123(3):294-306.

PMID: 38115583 PMC: 10870137. DOI: 10.1016/j.bpj.2023.12.015.


Host-mediated RNA editing in viruses.

Zhu T, Niu G, Zhang Y, Chen M, Li C, Hao L Biol Direct. 2023; 18(1):12.

PMID: 36978112 PMC: 10043548. DOI: 10.1186/s13062-023-00366-w.


Aromatic disulfides as potential inhibitors against interaction between deaminase APOBEC3G and HIV infectivity factor.

Yan X, Chen C, Wang C, Lan W, Wang J, Cao C Acta Biochim Biophys Sin (Shanghai). 2022; 54(5):725-735.

PMID: 35920198 PMC: 9828099. DOI: 10.3724/abbs.2022049.


APOBEC3B Potently Restricts HIV-2 but Not HIV-1 in a Vif-Dependent Manner.

Bandarra S, Miyagi E, Ribeiro A, Goncalves J, Strebel K, Barahona I J Virol. 2021; 95(23):e0117021.

PMID: 34523960 PMC: 8577350. DOI: 10.1128/JVI.01170-21.


References
1.
Mulder L, Harari A, Simon V . Cytidine deamination induced HIV-1 drug resistance. Proc Natl Acad Sci U S A. 2008; 105(14):5501-6. PMC: 2291111. DOI: 10.1073/pnas.0710190105. View

2.
Gifford R, Rhee S, Eriksson N, Liu T, Kiuchi M, Das A . Sequence editing by Apolipoprotein B RNA-editing catalytic component [corrected] and epidemiological surveillance of transmitted HIV-1 drug resistance. AIDS. 2008; 22(6):717-25. PMC: 2946849. DOI: 10.1097/QAD.0b013e3282f5e07a. View

3.
Khamsri B, Fujita M, Kamada K, Piroozmand A, Yamashita T, Uchiyama T . Effects of lysine to arginine mutations in HIV-1 Vif on its expression and viral infectivity. Int J Mol Med. 2006; 18(4):679-83. View

4.
Pillai S, Wong J, Barbour J . Turning up the volume on mutational pressure: is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3). Retrovirology. 2008; 5:26. PMC: 2323022. DOI: 10.1186/1742-4690-5-26. View

5.
Iwatani Y, Takeuchi H, Strebel K, Levin J . Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect. J Virol. 2006; 80(12):5992-6002. PMC: 1472592. DOI: 10.1128/JVI.02680-05. View